ArticleOncogene2026
KLF12-mediated suppression of androgen receptor accelerates metastasis in endometrioid endometrial carcinoma by activating epithelial-mesenchymal transition.
Article in Oncogene, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
For patients with advanced endometrioid endometrial carcinoma (EEC), prognosis remains poor due to the lack of effective therapeutic targets. Loss of androgen receptor (AR) expression is associated with the progression of EEC. However, the regulatory mechanisms remain unknown, limiting its application in prognostic prediction and targeted therapy. In this study, overexpression of KLF12 or loss of AR was strongly correlated with advanced clinical stage and poor patient outcomes. Functional experiments demonstrated that KLF12 upregulation suppressed AR expression and promoted EEC metastasis by enhancing epithelial-mesenchymal transition (EMT) both in vitro and in vivo. As determined by bioinformatics predictions and CUT&Tag analysis, KLF12 suppressed the transcriptional activity of the AR gene by binding to the promoter and intronic regions. These direct interactions were further confirmed through electrophoretic mobility shift assay (EMSA), ChIP-PCR, ChIP-qPCR and dual-luciferase reporter assays. This study identifies a novel KLF12-AR regulatory axis driving EEC metastasis and provides potential molecular targets for therapeutic intervention and prognostic evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.